KOSDAQIT & Software315640

Deepnoid

₩1,478▲ 1.30%2026-11-18 close
Market Cap
₩43.4B
Turnover
₩30,138,380
Volume
20K
Shares out.
29.4M
PER
—
PBR
1.9×
EPS
-₩547
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Medical AI Built on Industrial AI Revenue, Losses Persist

Deepnoid has grown revenue on an industrial AI base, but operating losses continue until its medical AI products convert into earnings.

  1. 1

    Revenue fell from KRW 10.8 billion in 2024 to KRW 7.47 billion in 2025, down 31.1%, and Q3 2026 revenue was KRW 439 million, down 79.9% year on year.

  2. 2

    The company posted operating losses in each year from 2022 through 2025, with the 2025 operating loss at KRW 10.6 billion (operating margin -141.3%).

  3. 3

    Total equity rose to KRW 28.5 billion at the end of 2025 from about KRW 19 billion a year earlier, and the debt ratio was 42.0%. Press reports tied the increase partly to a rights offering of about KRW 17.9 billion.

  4. 4

    Supply announcements for the M4CXR chest X-ray AI product continued through August and September 2026 at private and tertiary hospitals, but its revenue contribution is not yet visible in quarterly results.

  5. 5

    The price-to-book ratio sits in a premium range relative to net assets, and because the last four quarters were net losses, a price-to-earnings ratio cannot be calculated.

02

Business structure

Deepnoid was founded in 2008 and has built its core capability in medical image reading technology. The business comprises medical AI, industrial AI (machine vision and security), and digital transformation segments.

Industrial AI has been the larger revenue source: its share was 92.1% in 2024, and in Q1 2025 it accounted for 93.0% of revenue versus 7.0% for medical AI.

The main industrial AI example is a security screening system developed jointly with Korea Airports Corporation, installed at about 150 units across 14 domestic airports and others.

Core medical AI products are the M4CXR generative chest X-ray reading solution, DEEP:NEURO for cerebral aneurysm detection support, and DEEP:CHEST for multi-lung disease detection.

M4CXR supply to hospitals was announced from August 2026, starting at a private general hospital and extending to tertiary hospitals in September 2026. DEEP BrainSeg, a brain MRI quantification tool, received regulatory approval in August 2026.

DEEP:NEURO was also registered in a Japanese INDICATE program in June 2026, and the company set up a Dubai branch for Middle East expansion. A 2025 press report described Deepnoid as one of the domestic medical AI companies closest to turning profitable.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.2B-₩3B−139.2%
2025Q4₩700M-₩3.7B−564.6%
2026Q1₩400M-₩4B−1114.5%
2026Q2₩1.3B-₩3.3B−251.5%
2026Q3₩400M-₩3.7B−834.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩3.2B-₩6.2B-₩5.3B−193.6%−53.5%45.8%
2023₩1.9B-₩6.7B-₩6.7B−348.0%−24.8%26.7%
2024₩10.8B-₩10.1B-₩9.1B−93.1%−47.7%67.9%
2025₩7.5B-₩10.6B-₩10.7B−141.3%−37.7%42.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue was KRW 3.18 billion in 2022, KRW 1.93 billion in 2023 (down 39.2% year on year), KRW 10.8 billion in 2024 (up 461.1%), and KRW 7.47 billion in 2025 (down 31.1%). 2024 was the largest year and 2023 the smallest among 2022 to 2025.

Operating losses were KRW 6.16 billion, KRW 6.73 billion, KRW 10.1 billion, and KRW 10.6 billion over the same years, with operating margins of -193.6%, -348.0%, -93.1%, and -141.3%. Revenue rose sharply in 2024, and the operating margin improved from 2023, yet the operating loss in won terms widened.

Net losses attributable to controlling shareholders were KRW 5.33 billion, KRW 6.74 billion, KRW 9.08 billion, and KRW 10.7 billion, a loss every year from 2022 through 2025.

The company attributed the 2025 revenue decline to market changes in the machine vision AI end markets, and the wider loss to higher fixed costs such as personnel expenses from expanding medical AI R&D staff.

In the first half of 2025, gross profit rose about sixfold year on year, which was mainly attributed to better margins in industrial AI. The debt ratio was 45.8% in 2022, 26.7% in 2023, 67.9% in 2024, and 42.0% in 2025. Total equity rose from KRW 19 billion at the end of 2024 to KRW 28.5 billion at the end of 2025.

Operating cash flow was negative in all four years: -KRW 3.71 billion, -KRW 4.77 billion, -KRW 13.9 billion, and -KRW 6.36 billion. By quarter, revenue was KRW 2.18 billion in Q3 2025, KRW 659 million in Q4 2025, KRW 357 million in Q1 2026, KRW 1.31 billion in Q2 2026, and KRW 439 million in Q3 2026, swinging widely.

Operating losses were KRW 3.04 billion, KRW 3.72 billion, KRW 3.98 billion, KRW 3.3 billion, and KRW 3.66 billion over the same five quarters, and only Q2 2026 showed a narrower loss. Net losses attributable to controlling shareholders over the four quarters from Q4 2025 to Q3 2026 totaled KRW 15 billion.

05

Industry analysis

The pace of medical AI depends on hospital adoption and regulatory approval. The company has said the medical segment takes time because of approval procedures but is the largest market over the long run.

M4CXR was planned to enter clinical use on a non-reimbursed basis under the regulatory deferral system before moving toward insurance reimbursement. Deepnoid has also obtained MDSAP certification, a prerequisite for US and Japanese market entry.

On remote reading demand, a forecast cited in a 2025 report expected the GCC remote reading market to grow from USD 89 million in 2021 to USD 228 million in 2028. In industrial AI, the company attributed the 2025 revenue decline to changes in the market environment of its machine vision end markets.

In security AI, the company said it had delivered 32 sets to Korea Airports Corporation and was in talks with overseas airports. The two segments are moving in different directions, and the improved industrial AI margin in the first half of 2025 cushioned overall results. Timing for profitability differs among domestic medical AI companies.

06

Outlook

The company has stated a 2026 revenue target of KRW 10 billion. A 2025 press report said it expected to turn profitable as early as 2026, and the same report cited a 2025 revenue target of about KRW 20 billion against reported 2025 revenue of KRW 7.47 billion.

For M4CXR, the company in 2025 expected regulatory approval in Q1 2026 or in the first half of 2026, and hospital supply announcements followed from August 2026. The M4CT chest CT extension moved into a second-year project with a completed demo version.

An integrated AI reading platform for remote reading was targeted for development completion in the first half of 2026. On research, eight abstracts were accepted at KCR 2026, a best oral presentation award came from KoSAIM 2026, and the company ranked second in the BraTS-METS segment at MICCAI 2026.

It also joined a KRW 18 billion national R&D project, the Korean ARPA-H project, focused on elderly mental health AI.

The next checkpoints are whether revenue returns above the KRW 7.47 billion level of 2025 and whether the operating loss narrows from KRW 10.6 billion, and whether M4CXR supply shows up in quarterly revenue.

07

Valuation

PER
—
PBR
1.9×
ROE
-97.5%
EPS
-₩547
BPS
₩774
Dividend per share
₩0

Because the last four quarters were net losses, a price-to-earnings ratio cannot be calculated. The price-to-book ratio sits in a premium range relative to net assets, meaning the share price reflects business expectations more than asset value. The dividend yield is below the industry average.

At the end of 2025, total equity was KRW 28.5 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 12 billion. Because losses have run since 2022, historical earnings-based multiples offer limited comparison.

Capital raising improved financial capacity, but the premium to net assets will be read differently depending on whether earnings recover. Until earnings recovery is visible, asset and revenue indicators are the more usable reference points.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Expanding hospital supply for medical AI

M4CXR supply to hospitals expanded from a first private general hospital in August 2026 to a series of tertiary hospitals and a national reading hub in September 2026. Whether this shows up in quarterly revenue is the next point to confirm. DEEP:NEURO's registration in Japan's INDICATE program has set up a base for research cooperation there.

External recognition of research

The GLINT chest imaging research received the best oral presentation award at KoSAIM 2026, and the company placed second in the BraTS-METS segment at MICCAI 2026. The company says such research can underpin product upgrades and reading services, though academic recognition does not translate directly into revenue.

Improved financial capacity

Total equity rose to KRW 28.5 billion at the end of 2025 from about KRW 19 billion a year earlier, and the debt ratio fell from 67.9% in 2024 to 42.0% in 2025.

A rights offering of about KRW 17.9 billion was aimed at strengthening the balance sheet, and the company said proceeds would fund product approvals, commercialization, and overseas expansion.

09

Bear factors

Five consecutive quarters of operating losses

Operating losses have run for five consecutive quarters from Q3 2025 through Q3 2026. The Q3 2026 operating loss of KRW 3.66 billion widened from the prior quarter. Operating cash flow was also negative in all four years through 2025.

Revenue volatility and end-market demand

Revenue fell 31.1% in 2025, and the company attributed the decline to changes in the market environment of its machine vision AI end markets. Q3 2026 revenue was down 79.9% year on year, and quarterly revenue dropped from KRW 1.31 billion in Q2 2026 to KRW 439 million in Q3 2026. Because industrial AI makes up most revenue, weaker demand in that segment would move total revenue sharply.

Delays in the timing of profitability

Operating losses continued through Q3 2026, and the loss narrowed only in Q2 2026. Against a 2025 revenue target of about KRW 20 billion, reported 2025 revenue of KRW 7.47 billion was far lower, a gap that weighs on the profitability timeline.

10

Risk factors

Financial capacity and fundraising

With operating losses continuing, financial capacity relies on external funding such as rights offerings. Equity rose at the end of 2025, but operating cash flow was still -KRW 6.36 billion in 2025.

If further funding is needed, shareholder dilution could follow, and the company has kept the possibility of raising funds for medical AI investment open.

Regulatory approval and timing

Monetizing M4CXR depends on Ministry of Food and Drug Safety approval and insurance reimbursement listing. The company plans to enter the non-reimbursed market first and move toward reimbursement in stages.

Delays in approval or reimbursement would reduce visibility on medical AI revenue, and overseas expansion depends on local approval processes.

Business concentration and competition

Much of the revenue comes from industrial AI in machine vision and security, which leaves the company exposed to swings in those industries. In medical AI, domestic peers are also aiming for profitability, so competition for share is intense. R&D headcount has raised fixed costs, and if revenue growth is slow, losses could widen.

11

What to watch next

  1. Late January 2027 (expected)

    Annual 2026 results disclosure. The 2025 annual results were reported on January 27, 2026. Key points are whether revenue exceeds the 2025 level of KRW 7.47 billion and whether the operating loss narrows from KRW 10.6 billion.

  2. By March 31, 2027

    Filing of the 2026 annual business report. This is the point to check the full-year operating margin, operating cash flow, and the change in total equity on an audited basis. Regular filing figures become the confirmed reference, unlike preliminary quarterly figures.

  3. By May 15, 2027

    Q1 2027 quarterly report. The points are whether hospital supply of M4CXR shows up in quarterly revenue above the KRW 439 million level of Q3 2026, and whether the operating loss narrows from the KRW 3.66 billion level of Q3 2026.

12

Overall view

Deepnoid is expanding medical AI product approvals and hospital supply on a base where industrial AI accounts for most revenue. Operating losses ran in each year from 2022 through 2025, and 2025 revenue fell 31.1% to KRW 7.47 billion.

Operating losses have continued for five consecutive quarters through Q3 2026, and net losses attributable to controlling shareholders over the last four quarters totaled KRW 15 billion. On the balance sheet, total equity rose to KRW 28.5 billion at the end of 2025 and the debt ratio fell to 42.0%.

In medical AI, progress includes M4CXR hospital supply, a brain MRI approval, and overseas registration. At the same time, revenue remains sensitive to industrial AI demand. The next checkpoints are the operating margin in the 2026 annual report and whether Q1 2027 quarterly revenue reflects M4CXR supply.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.news.nate.com
  2. thinkpool.com
  3. ibtomato.com
  4. pharm.edaily.co.kr
  5. medicaltimes.com
  6. vegannews.co.kr
  7. m.ddaily.co.kr
  8. dailymedi.com
  9. mt.co.kr
  10. mdtoday.co.kr
  11. deepnoid.com
  12. newsway.co.kr
  13. website.dev.deepnoid.com
  14. biotimes.co.kr
  15. medifonews.com
  16. news.nate.com
  17. etoday.co.kr
  18. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis